Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Class-switched antibodies to double-stranded DNA (dsDNA) are prevalent and pathogenic in systemic lupus erythematosus (SLE), yet mechanisms of their development remain poorly understood. Humans and mice lacking secreted DNase DNASE1L3 develop rapid anti-dsDNA antibody responses and SLE-like disease. We report that anti-DNA responses in Dnase1l3−/− mice require CD40L-mediated T cell help, but proceed independently of germinal center formation via short-lived antibody-forming cells (AFCs) localized to extrafollicular regions. Type I interferon (IFN-I) signaling and IFN-I-producing plasmacytoid dendritic cells (pDCs) facilitate the differentiation of DNA-reactive AFCs in vivo and in vitro and are required for downstream manifestations of autoimmunity. Moreover, the endosomal DNA sensor TLR9 promotes anti-dsDNA responses and SLE-like disease in Dnase1l3−/− mice redundantly with another nucleic acid-sensing receptor, TLR7. These results establish extrafollicular B cell differentiation into short-lived AFCs as a key mechanism of anti-DNA autoreactivity and reveal a major contribution of pDCs, endosomal Toll-like receptors (TLRs), and IFN-I to this pathway.
[Display omitted]
•Anti-DNA antibody response is driven by T-dependent extrafollicular plasmablasts•IFN-I signaling propagates anti-DNA responses and SLE-like disease•IFN-I produced by pDCs promotes plasmablast proliferation and differentiation•TLR9 drives anti-DNA responses and autoimmunity redundantly with TLR7
Autoantibodies to self-DNA are a defining feature of systemic lupus erythematosus (SLE), yet the mechanisms of their development remain poorly understood. Soni et al. show that anti-DNA autoreactivity is driven by extrafollicular B cell differentiation into short-lived plasmablasts, which is facilitated by plasmacytoid dendritic cells, type I interferon, and endosomal Toll-like receptors 7 and 9.